First Clinical Trial Using GVG to Treat Addiction Shows Promising Results.(vigabatrin)

AScribe Health News Service, September, 2003

Byline: Brookhaven National Laboratory

UPTON, N.Y. Sept. 22 (AScribe Newswire) -- Using an experimental addiction treatment first investigated at the U.S. Department of Energy's Brookhaven National Laboratory, a team of scientists from Brookhaven, the New York University (NYU) School of Medicine, and a national addiction treatment center in Mexico report prolonged abstinence and the elimination of drug craving in eight out of 20 hardcore, long-term cocaine addicts who enrolled in the study. This is the first human clinical data showing that gamma vinyl-GABA (GVG, vigabatrin) holds promise as a pharmacological treatment for cocaine addiction. The results will appear in the Dec. 1, 2003, issue of the journal Synapse, available online Sept. 22, 2003...

Read the rest of this article with a Free Trial at HighBeam Research.

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works.